


Researchers describe novel immune syndrome

October 18 2018



CT scans show that the excessive inflammation and infection caused by the mutation in the *IKBKB* gene results in the thickening of bronchi in the lungs. Credit: Cardinez et al., 2018

Researchers from Australia and Japan have discovered a new human immunodeficiency syndrome in two patients on separate continents. The study, which will be published October 18 in the *Journal of Experimental Medicine*, reveals that a mutation in a gene called *IKBKB* disrupts the immune system, leading to excessive inflammation and the loss of both T and B white blood cells.

Genetic [mutations](#) can cause a wide variety of severe, inheritable immune deficiencies that begin at birth or in early childhood. But the causes of other, more sporadic, immune diseases, including milder immunodeficiencies that can develop later in life, remain poorly understood. A team of researchers led by Matthew C. Cook from Australian National University in Canberra and Hirokazu Kanegane from Tokyo Medical and Dental University analyzed a group of immunodeficient patients in Australia and Japan and identified two unrelated patients—one in each country—carrying an identical mutation in a gene called *IKBKB*.

Both patients seemed to have developed the mutation "de novo," rather than inheriting it from their parents. Their symptoms were slightly different, but they were both susceptible to recurrent infections and showed signs of excessive inflammation. Both patients had reduced numbers of antibody-producing B [cells](#) and two types of effector T cells that help the body fight off infections. However, the T cells that

remained appeared to be more prone to activation.

The *IKBKB* gene encodes an enzyme called IKK2 that controls the development and activation of [white blood cells](#) by regulating the NF-kB cell signaling pathway. Mutations that inhibit IKK2 and NF-kB signaling are known to cause severe early onset immune deficiencies. But the mutation found in the two Australian and Japanese patients seems to result in a hyperactive form of IKK2 that increases NF-kB cell signaling.

To confirm that this mutation was responsible for the patients' symptoms, the researchers used CRISPR/Cas9 gene editing to create the same mutation in mice. These animals also showed an increase in IKK2 and NF-kB cell signaling and developed similar defects in their T and B cells.

"Our results show that a de novo mutation in human *IKBKB* increases the function of IKK2 and results in a combined immune deficiency syndrome affecting both T and B cells," Kanegane says.

"We were able to confirm this by engineering an equivalent mutation in mice," says Cook. "In future, this strategy should prove important for investigating therapeutic interventions for personalized therapy."

More information: *Journal of Experimental Medicine* (2018). [DOI: 10.1084/jem.20180639](https://doi.org/10.1084/jem.20180639)

Provided by Rockefeller University Press

Citation: Researchers describe novel immune syndrome (2018, October 18) retrieved 4 February 2024 from <https://medicalxpress.com/news/2018-10-immune-syndrome.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.